Clark, A. S., Yau, C., Wolf, D. M., Petricoin, E. F., Veer, L. J. v. ‘., Yee, D., . . . DeMichele, A. M. (2021). Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nature Portfolio.
Chicago Style (17th ed.) CitationClark, Amy S., et al. Neoadjuvant T-DM1/pertuzumab and Paclitaxel/trastuzumab/pertuzumab for HER2+ Breast Cancer in the Adaptively Randomized I-SPY2 Trial. Nature Portfolio, 2021.
MLA (9th ed.) CitationClark, Amy S., et al. Neoadjuvant T-DM1/pertuzumab and Paclitaxel/trastuzumab/pertuzumab for HER2+ Breast Cancer in the Adaptively Randomized I-SPY2 Trial. Nature Portfolio, 2021.
Warning: These citations may not always be 100% accurate.